Effective Drug-Eluting Coronary Stents (DES) Using Engineered Nanocoatings

By AZoNano

Table of Contents

Introduction
Does ENS Meet the Challenge
Advantages of ENS Over Present Coating Methods
Uniqueness of the ENS process from Traditional Device-Coating Methodologies
About Nanocopoeia

Introduction

The medical device industry underwent a transformation with the drug-eluting coronary stent (DES) in 2003, creating a new line of "convergence products" that held tremendous potential to open arteries and prevent scar tissue (restenosis). However mid-2006 saw the downfall of the DES industry,which continued throughout 2007 due to problems with device performance and lack of patient compliance with much needed adjunct therapies.

The present challenge is to create next generation products that can address the disease mechanisms related to atherosclerosis. These therapies must target vessel reendothelialization and disease treatment, rather than purely mechanical support and scar tissue deterrence.

Almost all segments of the research population, including industry, academia and government feel that there is an urgent need for sophisticated products that address the therapeutic issues lacking in current products.

Does ElectroNanospray™ Meet the Challenge?

There are a large number of opportunities abound for technology that improves the therapeutic value of medical device coatings, which is a new generation of therapeutic coatings called "biologics" materials. The ElectroNanospray™ (ENS) process is ideal for this purpose. It is possible to apply nanoparticles as uniform coatings to the complex architecture, similar to those found in coronary stents. Coating characteristics can be modified to create surfaces ranging from a smooth film to progressively more "open matrix" coatings with drug: polymer combination nanoparticles of increasing size. These surface characteristics are related directly to the drug elution profile of the combination device.

Advantages of ElectroNanospray™ Over Present Coating Methods

The advantages of ENS are:

  • Enhanced coating efficiency in order to reduce waste of expensive materials
  • Non-line-of-sight coating for better adherence around struts and angles
  • Pharmaceutical agent deposition within the polymer matrix and onto the coating surface
  • Intentional design of continuous and/or pulsatile drug release
  • Capability of applying multi-laminate coatings targeting a specific time course release of multiple active agents
  • Differential coating of device surfaces to facilitate site-specific therapy

Uniqueness of the ENS process from Traditional Device-Coating Methodologies

The ENS process causes coatings that can be engineered to tune the drug's release profile. As mentioned above, the ENS process produces mono-disperse nanoscale particles of drugs and polymers. These particles can be applied to surfaces in a wide range of morphologies. In contrast, other spray techniques used to produce medical device coatings produce particles with diameters of 10-20 μm or larger that result in solvent-polymer droplets that flow as they hit the surface to form a conformal film. Nanocopoeia has determined that varying the structure of the polymer impacts drug release profiles.

Figure 1. The ElectroNanospray™ coating process is highly reproducible, as shown by this data. The coating in this case was a mixture of poly(lactide-co-ε-caprolactone) and dexamethasone.

About Nanocopoeia

Built on a foundation of revolutionary intellectual property, Nanocopoeia has grown into a major nanotechnology player in just 10 years. With beginnings at the University of Minnesota dating back to 2001, the company formally began operations in late 2003 after obtaining worldwide exclusive rights to the patent portfolio developed by Drs. David Pui and Da-Ren Chen. The core patents obtained from the University of Minnesota cover the use of ElectroNanospray™ to create nanoparticles out of virtually any material that can be put into solution or suspension. That patent estate has undergone continual updating and enhancing to broaden Nanocopoeia's claims both through the University and by the company during its operation.

This information has been sourced, reviewed and adapted from materials provided by Nanocopoeia.

For more information on this source, please visit Nanocopoeia.

Date Added: Jul 7, 2012 | Updated: Jul 15, 2013
Ask A Question

Do you have a question you'd like to ask regarding this article?

Leave your feedback
Submit